IBIO INC (IBIO) Stock Price & Overview
NASDAQ:IBIO • US4510337086
Current stock price
The current stock price of IBIO is 1.95 USD. Today IBIO is up by 2.63%. In the past month the price decreased by -31.1%. In the past year, price decreased by -39.53%.
IBIO Key Statistics
- Market Cap
- 67.353M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.18
- Dividend Yield
- N/A
IBIO Stock Performance
IBIO Stock Chart
IBIO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to IBIO. When comparing the yearly performance of all stocks, IBIO is a bad performer in the overall market: 86.11% of all stocks are doing better.
IBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IBIO. IBIO has a great financial health rating, but its profitability evaluates not so good.
IBIO Earnings
IBIO Forecast & Estimates
11 analysts have analysed IBIO and the average price target is 5.47 USD. This implies a price increase of 180.72% is expected in the next year compared to the current price of 1.95.
IBIO Groups
Sector & Classification
IBIO Financial Highlights
Over the last trailing twelve months IBIO reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 53.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.42% | ||
| ROE | -43.74% | ||
| Debt/Equity | 0 |
IBIO Ownership
IBIO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.49 | 380.121B | ||
| AMGN | AMGEN INC | 15.48 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.07 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.06 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.43 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.31 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IBIO
Company Profile
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2008-08-18. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. The company has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.
Company Info
IPO: 2008-08-18
IBIO INC
11750 Sorrento Valley Road, Suite 200
San Diego CALIFORNIA 77807 US
CEO: Thomas F. Isett
Employees: 20
Phone: 18009279800
IBIO INC / IBIO FAQ
What does IBIO INC do?
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2008-08-18. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. The company has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.
What is the current price of IBIO stock?
The current stock price of IBIO is 1.95 USD. The price increased by 2.63% in the last trading session.
Does IBIO stock pay dividends?
IBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of IBIO stock?
IBIO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists IBIO stock?
IBIO stock is listed on the Nasdaq exchange.
Who owns IBIO INC?
You can find the ownership structure of IBIO INC (IBIO) on the Ownership tab.
What is the Short Interest ratio of IBIO INC (IBIO) stock?
The outstanding short interest for IBIO INC (IBIO) is 13.19% of its float.